Feb 11 (Reuters) - Eli Lilly (NYSE:LLY) and Co LLY.N :
* HEALTH CANADA HAS APPROVED TALTZ® (IXEKIZUMAB) FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS (RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS)
* ELI LILLY CANADA SAYS HEALTH CANADA APPROVED TALTZ ON FEB 4, 2020, FOR TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS